Evogene Ltd. SEC Filings

Evogene Ltd. director Percy Adrian John filed an initial ownership report detailing his stock option holdings in the company. The filing lists several option awards over ordinary shares with exercise prices ranging from 1.2900 to 62.6800 and expirations between 2028 and 2035.

These options cover blocks of 250 to 2,500 underlying ordinary shares each. One grant over 2,500 underlying shares at an exercise price of 1.2900 vests in four equal quarterly installments so that it is fully vested on the one-year anniversary of the August 18, 2025 grant date. The report reflects holdings only, not new market transactions.

Evogene Ltd. Chief Development Officer Gabi Tarcic filed an initial ownership report showing a stock option position. The option gives the right to buy 40,000 ordinary shares at an exercise price of $2.305 per share and expires on November 20, 2034.

According to the vesting terms, 25% of the options vest on the first anniversary of the November 20, 2024 grant date. The remaining options vest in equal quarterly installments of 6.25% over the next twelve quarters, so all options are fully vested four years after the grant date.

Evogene Ltd. filed an initial ownership report for Chief Technology Officer Ilia Zhidkov, detailing his stock option holdings in the company. The filing lists multiple options to buy ordinary shares with exercise prices ranging from 2.3050 to 49.4700 and expiration dates between 2027 and 2034. Footnotes state that certain grants from March 8, 2023 and November 20, 2024 vest 6.25% each quarter over four years until fully vested on their fourth anniversaries.

Evogene Ltd. director Sarit Firon filed an initial Form 3 disclosing stock option holdings in the company. The filing lists multiple stock option grants over ordinary shares with exercise prices ranging from 1.2900 to 70.5500 per share and expiration dates between 2026 and 2035. One grant for options over 2,500 ordinary shares at an exercise price of 1.2900 vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.

Evogene Ltd. filed a Form 3 detailing the equity holdings of its Chief Financial Officer, Eldad Yaron. He holds 4,100 ordinary shares underlying restricted share units that began vesting on April 1, 2023 at 6.25% per quarter over four years.

He also holds stock options over 15,000 ordinary shares at an exercise price of 12.584 per share, vesting from March 30, 2022 with 25% after one year and 6.25% per quarter thereafter until fully vested on the four-year anniversary. Additional options cover 60,000 ordinary shares at an exercise price of 2.300 per share, vesting 6.25% per quarter over four years from November 20, 2024.

Evogene Ltd. director and President & CEO Haviv Ofer filed an initial ownership report showing he holds stock options over ordinary shares in the company. These include options over 22,500 shares at an exercise price of 51.9600 per share expiring on August 8, 2027, 50,000 shares at 10.5000 per share expiring on April 21, 2030, and 52,800 shares at 1.6600 per share expiring on December 23, 2034. A footnote explains that the options granted on December 23, 2024 vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal quarterly installments of 6.25% over the next twelve quarters.

Evogene Ltd. director Falk Dan Michael reported his initial holdings of stock options linked to the company’s ordinary shares. The Form 3 shows four option grants with exercise prices of $10.51, $6.03, $7.16, and $1.29 per share and expiration dates ranging from September 2032 to August 2035. These options cover 1,800, 1,800, 1,800 and 2,500 underlying ordinary shares, all held directly. A footnote explains that the 2,500-share grant vests in four equal quarterly installments of 25% each, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.

Evogene Ltd. reported 2025 results showing a smaller overall loss alongside a major strategic shift toward its ChemPass AI generative small‑molecule platform. Net loss for 2025 narrowed to approximately $7.8 million from about $18.1 million, mainly due to lower operating expenses and a $6.4 million gain on the sale of Lavie Bio and MicroBoost AI for Ag to ICL, recorded in $5.7 million of income from discontinued operations.

Full‑year revenues fell to roughly $3.9 million from $5.6 million as certain AgPlenus and Corteva revenues and Casterra seed sales declined. A $2.2 million Casterra inventory impairment pushed 2025 cost of revenues to about $4.1 million, driving an operating loss of $14.0 million. Cash, cash equivalents and short‑term deposits were about $13.0 million at year‑end, after using $13.5 million in operating cash during 2025, while management exited non‑core assets, resized the organization and highlighted new AI collaborations with Google Cloud in pharma and agriculture.

Evogene Ltd. is outlining a strategic transformation centered on its ChemPass AI™ computational chemistry engine. After reassessing its technology and capital allocation in 2025, the company chose to focus resources on designing small molecules for two core markets: human health therapeutics and agricultural chemicals.

Evogene consolidated activity around ChemPass AI™, discontinued non-core work, divested misaligned subsidiaries, resized its organization and built a business development team aligned with this focused strategy. The platform operates on a 38‑billion‑molecule universe, aiming to generate novel, highly active, synthesizable compounds that meet complex multi‑parameter development requirements from the outset.

The company highlights collaborations in human health with biotechnology and academic partners, and in agriculture through its AgPlenus subsidiary, including relationships with Bayer and Corteva. It reports completion of key divestments, such as Lavie Bio’s sale to ICL and licensing of Biomica’s lead oncology candidate to Lishan Pharmaceuticals, while retaining exposure to assets like Casterra.